Document is current
Any future updates will be listed below
-
Authors
Makhlouf, Ahmed T. https://orcid.org/0000-0001-8068-522X
Drew, William https://orcid.org/0000-0002-9178-8731
Stubbs, Jacob L. https://orcid.org/0000-0002-6634-2228
Taylor, Joseph J. https://orcid.org/0000-0002-9185-0427
Liloia, Donato https://orcid.org/0000-0002-9481-8510
Grafman, Jordan https://orcid.org/0000-0001-8645-4457
Silbersweig, David
Fox, Michael D. https://orcid.org/0000-0001-8848-6399
Siddiqi, Shan H. https://orcid.org/0000-0002-0967-9289
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01MH113929, K23MH129829 and R01MH113929, R01MH113929, R21MH126271, R56AG069086, R01MH115949, and R01AG060987, K23MH121657, R21MH126271, and R01MH136248)
Harvard Medical School (Dupont Warren Fellowship Award, Dupont Warren Fellowship Award and Livingston Award)
University of British Columbia (Friedman Award for Scholars in Health)
Gouvernement du Canada | Canadian Institutes of Health Research (Vanier Scholarship)
Brain and Behavior Research Foundation (Young Investigator Grant (no. 31081), Young Investigator Grant)
Sidney R. Baer, Jr. Foundation
Baszucki Brain Research Fund
The Nancy Lurie Marks Foundation, the Kaye Family Research Endowment, the Baszucki Brain Research Fund
U.S. Department of Veterans Affairs (I01CX002293)
the Baszucki Brain Research Fund
- License Information
-
More Information
Article History
Received: 12 October 2023
Accepted: 7 October 2024
First Online: 12 December 2024
Competing interests
: S.H.S. holds intellectual property related to using individualized resting-state network mapping for targeting TMS, filed in 2016, which has not generated royalties and is unrelated to this work. S.H.S. also serves as a scientific consultant for Magnus Medical, has received investigator-initiated research funding from Neuronetics (2019) and Brainsway (2022), received speaking fees from Brainsway (2021) and Otsuka (for PsychU.org, 2021) and holds shares in Brainsway (publicly traded) and Magnus Medical (privately held). M.D.F. is a scientific consultant for Magnus Medical and owns separate intellectual property related to using functional connectivity to target TMS for depression, filed in 2013, which has not generated royalties and is unrelated to this work. The other authors declare no competing interests.
